NORTHERN NEW JERSY COMMUNITY ONCOLOGY PROGRAM

描述：(申请者描述)新泽西州北部CCOP (NNJCCOP)为国家合作小组临床提供地区性访问 在新泽西州以及与新泽西州接壤的50%以上的人口中进行试验 约克市。NNJCCOP为医生提供了访问五个研究基地的机会。六十 医生，包括25名内科肿瘤学家，可以访问 ECOG、NSABP、URCC和PCPT的SWOG。19名内科医生，其中8名 儿科血液学家/肿瘤学家是POG的成员。八名内科医生 与内科和儿科肿瘤学家合作。总共71个 医生目前参加了NNJCCOP。 在5个城市的5家组成医院有6个临床站点： Hackensack大学医学中心(HUMC)有两个临床 地点：明日儿童研究所(TCI)和新泽西州北部 癌症中心(NNJCC)；伊丽莎白普通医疗中心 (EGMC)；在莫里斯敦，莫里斯敦纪念医院(MMH)；在Summit， Overiook医院；在蒙特克莱尔，山腰医院 (MSH)。组件医院访问了近5000名新诊断的癌症患者 每年都有病人，占医院床位2500多张。 这项提案的总体目标是降低癌症发病率， 病态，和死亡率通过加速转移新开发的 癌症预防、早期发现、治疗、病人管理、 康复和持续护理技术推广到广泛的社区 申请。 有几个目标：为NCI赞助的试验提供地区性准入， 增加妇女和少数群体，扩大NNJCCOP在 研究基地，通过质量保持卓越标准 保证措施，并通过以下方式加强癌症控制贡献 接触到更多的初级保健医生和专家。 这些方法包括一个由医院和调查人员组成的地区性财团 由执行委员会管理，并通过NNJCCOP C协调 在S财团办公室；招聘、留住和 合规性；协议管理、研究的政策和程序 记录和药品分销；精心设计和执行的质量 控制和保障措施。工作人员分配特别侧重于 对骨髓移植研究、BCPT和PCPT的应计费用。 1997年至2002年，超过1,300个CCOP学分或至少272.9个CCOP学分 预计每年将有154.5个治疗学分和118.4个癌症控制 学分。

DESCRIPTION: (Applicant's Description) The Northern New Jersey CCOP (NNJCCOP) provides regional access to national cooperative group clinical trials to over 50% of the population of New Jersey as well as bordering New York. The NNJCCOP provides physician access to five research bases. Sixty physicians, including 25 medical oncologists, have access to studies in ECOG, NSABP, URCC a n d SWOG for the PCPT. Nineteen physicians, including 8 pediatric hematologists/oncologists, are members of POG. Eight physicians collaborate with both medical and pediatric oncologists. Altogether 71 physicians currently participate in the NNJCCOP. There are 6 clinical sites at 5 component hospitals in 5 cities: in Hackensack, the Hackensack University Medical Center (HUMC) has two clinical sites: the Tomorrows Children's Institute (TCI) and the Northern New Jersey Cancer Center (NNJCC); in Elizabeth, the Elizabeth General Medical Center (EGMC); in Morristown, the Morristown Memorial Hospital (MMH); in Summit, the Overiook Hospital (OH); and in Montclair, the Mountainside Hospital (MSH). The component hospitals access nearly 5000 newly diagnosed cancer patients a year and account for over 2500 hospital beds. The overall objective of this proposal is to reduce cancer incidence, morbidfty, and mortality by accelerating the transfer of newly developed cancer prevention, early detection, treatment, patient management, rehabilitation, and continuing care technology to widespread community application. There are several aims: to provide regional access to NCI-sponsored trials, to increase women and minorities, to expand NNJCCOP influence at the research bases, to maintain standards of excellence through quality assurance measures, and to enhance cancer control contributions through reaching more primary care physicians and specialists. The methods include a regional consortium of hospitals and investigators who are govened by an Executive Committee and coordinated through the NNJCCOP C o n s ortium Office; common approaches to recruitment, retention, and compliance; policies and procedures for protocol management, research records, and drug distribution; carefully designed and executed quality control and assurance measures. Staff assignments particularly focus on accruial to Bone Marrow Transplant studies, the BCPT, and the PCPT. Between 1997 and 2002, over 1300 CCOP credits or at least 272.9 CCOP credits a year are projected with 154.5 treatment credits and 118.4 cancer control credits.